Literature DB >> 30817278

Surgical management of renal cell carcinoma with associated tumor thrombus extending into the inferior vena cava: A 10-year single-center experience.

Ramazan Topaktaş1, Ahmet Ürkmez1, Emre Tokuç1, Rıdvan Kayar1, Hüseyin Kanberoğlu1, Metin İshak Öztürk1.   

Abstract

OBJECTIVE: Renal cell carcinoma (RCC) is a tumor that has a tendency of vascular invasion by extending to the inferior vena cava (IVC) after the renal vein. The total resection of the renal tumor and tumor thrombus is considered the optimal treatment. In our study, we aimed to present the results related to 34 consecutive cases of RCC with tumor thrombus.
MATERIAL AND METHODS: Of the 442 patients diagnosed with renal tumors between January 2008 and January 2018, 34 (7.6%) had tumor thrombus over the renal vein extending to the IVC. The data of the 34 patients with tumor thrombus were retrospectively reviewed and included in the study. All the 34 patients underwent radical nephrectomy with tumor thrombectomy. The presence of thrombus was evaluated using contrast-enhanced abdominal tomography, magnetic resonance imaging, or color Doppler ultrasonography. The level of thrombus was classified using the Mayo Clinic tumor thrombus classification. Surgery was performed transperitoneally through a modified Chevron incision and mostly in collaboration with other clinics. Complications were classified according to the Clavien system.
RESULTS: Of the 34 patients, 22 were males and 12 were females. The mean follow-up period was 36±27.2 months in patients who had a mean age of 61±10.9 years. The mean tumor size was 10.5±3.3 cm. The number of patients according to the thrombus levels I, II, and III were 20, 9, and 5, respectively. The average blood loss was 744±285.4 mL. Radical surgery for all patients who had direct invasion to the vena cava wall and/or level II and III was performed by gastrointestinal and cardiothoracic surgeons. Cardiopulmonary bypass was not performed in any patient. Minor complications (Clavien grades 1-2) were seen in 8 (23.5%) patients, while 2 (5.8%) patients had major complications (Clavien grades 3-5). The mean follow-up period was 36 months (range, 6-72 months). The overall 5-year survival rate was 85.2%.
CONCLUSION: We think that radical nephrectomy and caval thrombectomy is a safe and effective method in patients with RCC without tumor exceeding the diaphragmatic level. We believe that the surgical success rate can be increased using a multidisciplinary approach in selected cases.

Entities:  

Year:  2019        PMID: 30817278      PMCID: PMC6739079          DOI: 10.5152/tud.2019.95826

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  22 in total

Review 1.  Contemporary management of renal tumors with venous tumor thrombus.

Authors:  Frédéric Pouliot; Brian Shuch; Jeffrey C Larochelle; Allan Pantuck; Arie S Belldegrun
Journal:  J Urol       Date:  2010-09       Impact factor: 7.450

2.  Proposed classification of complications of surgery with examples of utility in cholecystectomy.

Authors:  P A Clavien; J R Sanabria; S M Strasberg
Journal:  Surgery       Date:  1992-05       Impact factor: 3.982

Review 3.  Renal cell carcinoma: vena caval involvement.

Authors:  Stephen A Boorjian; Shomik Sengupta; Michael L Blute
Journal:  BJU Int       Date:  2007-05       Impact factor: 5.588

4.  Surgical management of renal cell carcinoma with tumor thrombus in the renal and inferior vena cava: the University of Miami experience in using liver transplantation techniques.

Authors:  Gaetano Ciancio; Alan S Livingstone; Mark Soloway
Journal:  Eur Urol       Date:  2006-12-08       Impact factor: 20.096

5.  Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.

Authors:  Amnon Zisman; Jeff A Wieder; Allan J Pantuck; Debby H Chao; Frederick Dorey; Jonathan W Said; Barbara J Gitlitz; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

6.  Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.

Authors:  Bernd Wagner; Jean-Jacques Patard; Arnaud Méjean; Karim Bensalah; Grégory Verhoest; Richard Zigeuner; Vincenzo Ficarra; Jacques Tostain; Peter Mulders; Denis Chautard; Jean-Luc Descotes; Alexandre de la Taille; Laurent Salomon; Tommaso Prayer-Galetti; Luca Cindolo; Antoine Valéri; Nicolas Meyer; Didier Jacqmin; Hervé Lang
Journal:  Eur Urol       Date:  2008-08-05       Impact factor: 20.096

7.  Renal cell carcinoma with inferior vena caval involvement.

Authors:  W D Suggs; R B Smith; T F Dodson; A A Salam; S D Graham
Journal:  J Vasc Surg       Date:  1991-09       Impact factor: 4.268

8.  Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?

Authors:  Hyung L Kim; Amnon Zisman; Ken-Ryu Han; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

9.  The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus.

Authors:  Michael L Blute; Bradley C Leibovich; Christine M Lohse; John C Cheville; Horst Zincke
Journal:  BJU Int       Date:  2004-07       Impact factor: 5.588

10.  Renal carcinoma with supradiaphragmatic tumor thrombus: avoiding sternotomy and cardiopulmonary bypass.

Authors:  Gaetano Ciancio; Samir P Shirodkar; Mark S Soloway; Alan S Livingstone; Michael Barron; Tomas A Salerno
Journal:  Ann Thorac Surg       Date:  2010-02       Impact factor: 4.330

View more
  2 in total

1.  Experience with management of renal cell carcinoma with inferior vena cava/right atrial tumor thrombus.

Authors:  Shitangsu Kakoti; Rahul Jena; Sanjoy Kumar Sureka; Aneesh Srivastava; Anil Mandhani; Uday Pratap Singh
Journal:  Indian J Urol       Date:  2021-07-01

2.  Anesthesia and perioperative management for giant adrenal Ewing's sarcoma with inferior vena cava and right atrium tumor thrombus: A case report.

Authors:  Ji-Lian Wang; Chuan-Ya Xu; Chun-Jing Geng; Lei Liu; Ming-Zhu Zhang; Hua Wang; Ruo-Tao Xiao; Lu Liu; Geng Zhang; Cheng Ni; Xiang-Yang Guo
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.